Abstracts tagged "genomics"

Abstract Number: 660 • 2012 ACR/ARHP Annual Meeting
Abnormal Neutrophil Development in Human Systemic Lupus Erythematosus
Namrata Singh¹, Mariana J. Kaplan², Philip L. Cohen³ and Michael F. Denny³, ¹Internal Medicine, Temple University, Philadelphia, PA, ²Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ³Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: Recent research has increased the appreciation of the contributions of neutrophils to systemic lupus erythematosus (SLE). An abnormal circulating pool of granulocytes has been…
Abstract Number: 1475 • 2012 ACR/ARHP Annual Meeting
Does Skin Gene Expression Profile Predict Response to Imatinib?
Shervin Assassi¹, Jeffrey T. Chang², Dinesh Khanna³, Xiaochun Liu¹, Daniel Furst⁴ and Maureen D. Mayes⁵, ¹Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ²University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Imatinib is a potent inhibitor of TGF-β signaling. Furthermore, a subgroup of SSc patients shows a prominent TGF-β gene expression signature in skin biopsy…
Abstract Number: 522 • 2012 ACR/ARHP Annual Meeting
Genetic Variation in the NCR3 Locus Is Associated with Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in Scandinavian Samples
Gunnel Nordmark¹, Maija-Leena Eloranta¹, Per Eriksson², Elke Theander³, Helena Forsblad-d'Elia⁴, Roald Omdal⁵, Marie Wahren-Herlenius⁶, Roland Jonsson⁷ and Lars Rönnblom¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Dept of Rheumatology, Skane University Hospital, Lund University, Malmö, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁶Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Candidate gene studies in primary Sjögren’s syndrome (pSS) have identified polymorphisms in genes involved in the type I interferon (IFN) system and the type…
Abstract Number: 1180 • 2012 ACR/ARHP Annual Meeting
The Sex-Determining Region Y Box 6 Locus: Shared Genetic Susceptibility Between Rheumatoid Arthritis and Psychotic Disorder
Tony R. Merriman¹, Nicola Dalbeth², Andrew Harrison³, John Highton⁴, Lisa K. Stamp⁵, Malcolm D. Smith⁶, Benedicte A. Lie⁷, Tore K. Kvien⁸, Timothy Radstake⁹, Marieke J.H. Coenen¹⁰, Barbara Franke¹¹, Jasper Broen¹², Piet Van Riel¹³, Pilar Barrera¹⁴, Sophia Steer¹⁵, Marilyn E. Merriman¹, Amanda Phipps-Green¹, Ruth Topless¹, Mansour Zamanpoor¹⁶ and Wan Rohani Wan Tain¹⁷, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Rheumatology Unit, Hutt Hospital, Lower Hutt, New Zealand, ⁴Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand, ⁵Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁶Rheumatology Research Unit, Rheumatologist, Adelaide, Australia, ⁷Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ⁸Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, Radboud University Nijmegen Medical Centre, University Medical Center Utrecht, Nijmegen, Utrecht, Netherlands, ¹⁰Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹¹Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Department of Rheumatology & Clinical Immunology, University Medical Center, Utrecht, Netherlands, ¹³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵1 Sloane Ct East Flat 7, London, United Kingdom, ¹⁶University of Otago, Dunedin, New Zealand, ¹⁷Human Genome Center, School of Medical Sciences, Universiti Sains Malaysia, Malaysia
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease and schizophrenia (SZ) is a common psychotic disorder. There is an established negative association between RA…
Abstract Number: 433 • 2012 ACR/ARHP Annual Meeting
Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries
Marieke J.H. Coenen¹, Masha Umicevic-Mirkov², Hans Scheffer², Sophine B. Krintel³, Sita H. Vermeulen⁴, Julia S. Johansen³, Wietske Kievit⁵, Mart A.F.J. van de Laar⁶, Piet L.C.M. van Riel⁵, Barbara Franke² and Merete L. Hetland⁷, ¹Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³DANBIO and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁴Human Genetics and Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Department of Rheumatology and DREAM registry, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) rate pain relief as the highest priority in treatment outcome, and tumor necrosis factor inhibitors (anti-TNF) have proven very…
Abstract Number: 996 • 2012 ACR/ARHP Annual Meeting
Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial
Stella Aslibekyan¹, Elizabeth Brown², Richard J. Reynolds³, David T. Redden⁴, Sarah L. Morgan⁵, Joseph Baggott¹, Jin Sha¹, Larry W. Moreland⁶, James R. O'Dell⁷, Jeffrey R. Curtis⁸, S. Louis Bridges Jr.⁹ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁸Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment efficacy and toxicity remains…
Abstract Number: 424 • 2012 ACR/ARHP Annual Meeting
Influence of Pregnancy On Disease Activity-Associated Genes in Rheumatoid Arthritis
Erik J. Peterson¹, Shreyasee Amin², Hatice Bilgic³, Emily Baechler Gillespie³, Jane E. Salmon⁴, Ann M. Reed⁵, Weihua Guan⁶ and Daniel L. Mueller¹, ¹Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Minnesota Medical School, Minneapolis, MN, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶University of Minnesota School of Public Health, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) disease activity can often quiesce during pregnancy. Nevertheless, most women will experience a disease flare postpartum (PP). We hypothesized that changes…
Abstract Number: 997 • 2012 ACR/ARHP Annual Meeting
Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis
Stella Aslibekyan¹, Maria I. Danila², Jin Sha¹, David T. Redden³, Richard J. Reynolds⁴, Elizabeth Brown⁵, Laura B. Hughes⁶, Molly S. Bray¹, Sarah L. Morgan⁷, Larry W. Moreland⁸, James R. O'Dell⁹, Jeffrey R. Curtis¹⁰, Robert P. Kimberly¹¹, Lindsey A. Criswell¹², Robert M. Plenge¹³, S. Louis Bridges Jr.¹⁴ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ⁶Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama Birmingham, Birmingham, AL, ⁸Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ¹⁰Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹³Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a disease-modifying anti-rheumatic drug used as first-line therapy in rheumatoid arthritis (RA), is characterized by considerable heterogeneity in individual treatment response. We…
Abstract Number: 409 • 2012 ACR/ARHP Annual Meeting
Pathway Analysis of Genome-Wide Association Studies On Rheumatoid Arthritis
Young Ho Lee¹, Sung Jae Choi², Jong Dae Ji² and Gwan Gyu Song³, ¹Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Rheumatology, Korea University Medical Center, Seoul, South Korea, ³Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea
Background/Purpose: Genome-wide association studies (GWASs) have been successfully used to identify novel common genetic variants that contribute to susceptibility to complex diseases, but individual GWASs…
Abstract Number: 998 • 2012 ACR/ARHP Annual Meeting
Association Study of Genetic Risk Variants for Psoriasis in a Large Cohort of Psoriatic Arthritis, Psoriasis and Controls of the Spanish Population and Association with Relevant Clinical Subphenotypes
J. D. Cañete¹, Jose Luis Fernandez-Sueiro², Raimon Sanmarti³, Jesus Rodriguez⁴, Jordi Gratacós⁵, Rubén Queiro⁶, Juan Carlos Torre-Alonso⁷, Jose Perez Venegas⁸, Santiago Muñoz-Fernandez⁹, Carlos Gonzalez¹⁰, Carlos Montilla¹¹, Daniel Roig¹², Alba Erra¹³, Isabel Acosta¹⁴, Antonio Fernández-Nebro¹⁵, Pedro Zarco¹⁶, Arnald Alonso¹⁷, María América López-Lasanta¹⁷, Antonio Julià¹⁷, Raül Tortosa¹⁷ and Sara Marsal¹⁸, ¹Unitat d'Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona,, Barcelona, Spain, ²Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Rheumatology Service, Hospital Parc Taulí, Sabadell (Barcelona), ⁶Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷Rheumatology Service, Hospital Monte Naranco, Oviedo, Spain, ⁸Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, ⁹Rheumatology Service, Hospital Infanta Sofía, Madrid, Spain, ¹⁰Rheumatology Service, Hospital Gregorio Marañon, Madrid, Spain, ¹¹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, ¹³Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁴Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁵Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹⁶Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ¹⁷Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁸Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease with a substantial genetic risk component (first-degree relative risk ~ 55). Recently, Genomewide Association Studies (GWAS) have…
Abstract Number: 313 • 2012 ACR/ARHP Annual Meeting
Epigenetic Changes in Fibrosis and Myocyte Repair Genes May Contribute to Pathogenesis in Monozygotic Twins Discordant for Cardiac Manifestations of Neonatal Lupus
Paula S. Ramos¹, Timothy D. Howard², Miranda C. Marion³, Satria Sajuthi⁴, Robert M. Clancy⁵, Jill P. Buyon⁶ and Carl D. Langefeld⁴, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Cardiac manifestations of neonatal lupus (cardiac-NL) which comprise conduction defects and cardiomyopathy, occur in fetuses exposed to maternal anti-Ro antibodies and carry a case…
Abstract Number: 999 • 2012 ACR/ARHP Annual Meeting
Identification of New Epistatic Interactions with the HLA Region in the Genetic Etiology of Psoriasis and Psoriatic Arthritis
Sara Marsal¹, Juan D. Cañete², Jose Luis Fernandez-Sueiro³, Raimon Sanmarti², Jesus Rodriguez Moreno⁴, Jordi Gratacós⁵, Rubén Queiro⁶, Carlos Montilla⁷, Juan Carlos Torre-Alonso⁸, Jose Perez Venegas⁹, Santiago Muñoz-Fernández¹⁰, Carlos M. Gonzalez¹¹, Daniel Roig¹², Alba Erra¹³, Isabel Acosta¹, Antonio Fernández-Nebro¹⁴, Pedro Zarco¹⁵, Arnald Alonso¹⁶, María América López-Lasanta¹⁶, Raül Tortosa¹⁶ and Antonio Julià¹⁶, ¹Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁴Rheumatology Service, Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Rheumatology Service, Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain, ⁶Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ⁸H. Monte Naranco, Oviedo, Spain, ⁹Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, ¹⁰Unit Rheumatology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain, ¹¹Rheumatology, Hospital Gregorio Maranon, Madrid, Spain, ¹²Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, ¹³Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁴Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹⁵Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ¹⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease and is present in ~11% in patients with Psoriasis (Ps). Recently, Genomewide Association Studies (GWAS) have expanded…
Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting
Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Julie Ducreux¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez³ and Bernard Lauwerys³, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
Abstract Number: 976 • 2012 ACR/ARHP Annual Meeting
Effect of Interactions Between Validated Rheumatoid Arthritis Genetic Factors and Environmental Factors On Rheumatoid Arthritis Risk
Chia-Yen Chen¹, Linda T. Hiraki², Susan Malspeis³, Jing Cui⁴, Bing Lu⁴, Robert M. Plenge⁵, Karen H. Costenbader⁴ and Elizabeth W. Karlson⁶, ¹Department of Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Studies have shown associations between environmental factors and rheumatoid arthritis (RA) risk. Also, genome-wide association studies (GWAS) have identified genetic markers associated with RA…
Abstract Number: 2671 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjögren’s Syndrome
Christopher J. Lessard¹, He Li², Indra Adrianto³, John A. Ice³, Roland Jonsson⁴, Gabor G. Illei⁵, Maureen Rischmueller⁶, Gunnel Nordmark⁷, Xavier Mariette⁸, Corinne Miceli-Richard⁹, Marie Wahren-Herlenius¹⁰, Torsten Witte¹¹, Michael T. Brennan¹², Roald Omdal¹³, Patrick M. Gaffney³, James A. Lessard¹⁴, Wan-Fai Ng¹⁵, Nelson L. Rhodus¹⁶, Barbara M. Segal¹⁷, R. Hal Scofield¹⁸, Judith A. James¹⁹, Juan-Manuel Anaya²⁰, John B. Harley²¹, Courtney G. Montgomery³ and Kathy Moser Sivils¹⁹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway, ⁵Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁶Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁹Hopital Bicêtre, Le Kremlin Bicêtre, France, ¹⁰Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹²Nidcr NIH, Carolinas Medical Center, Charlotte, NC, ¹³Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹⁴Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁵Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ²¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].